Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

27
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
07/24/2014 07/25/2014 07/28/2014 07/29/2014 07/30/2014 Date
69.5(c) 72.25(c) 72(c) 72.53(c) 73.65 Last
35 585 185 582 154 883 100 256 69 031 Volume
+1.31% +3.96% -0.35% +0.74% +1.54% Change
More quotes
Company
MorphoSys AG is engaged in the development of antibodies for therapeutic, diagnostic, and research applications. It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec. The Partnered Discovery segment involves technologies for the generation of... 
Sector
Biotechnology & Medical Research
Calendar
09/25 | 02:00amPresentation
Surperformance© rating of MorphoSys AG
Trading Rating : Investor Rating :
More about the company
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 61,1 M
EBIT 2014 -12,9 M
Net income 2014 -10,1 M
Finance 2014 170 M
Yield 2014 -
Sales 2015 74,9 M
EBIT 2015 -3,73 M
Net income 2015 -10,1 M
Finance 2015 158 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 28,5x
EV / Sales 2015 23,4x
Capitalization 1 913 M
More Financials
Latest news on MORPHOSYS AG
2d ago MorphoSys AG Reports Results for the First Six Months of 2014
2d ago CELGENE : MorphoSys Provides Update on the Company's Proprietary Drug Portfolio
07/23 GALAPAGOS : MorphoSys and Galapagos Advance Joint Antibody Program in Inflammato..
07/21 MORPHOSYS : to Host Q2 2014 Conference Call on 28 July 2014
07/21 MORPHOSYS : Receives Additional Patents on Novel Antibody Platform Ylanthia in t..
07/18 MORPHOSYS : Receives Additional Patents on Novel Antibody Platform Ylanthia in t..
06/12 MORPHOSYS : and Merck Serono Enter Strategic Immuno-Oncology Collaboration
06/04 MORPHOSYS : Patent Issued for Melibiose Operon Expression System
06/02 MORPHOSYS : to Present at Four Investor Conferences in June
05/27 MORPHOSYS : Annual General Meeting of MorphoSys AG Approves All Proposals of the..
05/23 MORPHOSYS : Annual General Meeting of MorphoSys AG Approves All Proposals of the..
05/20 MorphoSys's MOR208 Program to Receive Orphan Drug Designation from FDA and EM..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
MorphoSys AG : Income Statement Evolution
More Financials
EPS Revisions
MorphoSys AG : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF